Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies
Open Access
Abstract
Background and Aims: While transarterial chemoembolization (TACE) represents a standard of therapy for intermediate-stage hepatocellular carcinoma (HCC) and is also routinely performed in patients with liver metastases, it is still debated which patients represent the ideal candidates for TACE therapy in terms of overall survival. Sarcopenia, the degenerative loss of skeletal muscle mass and strength, has been associated with an adverse outcome for various malignancies, but its role in the context of TACE has largely remained unknown. Here, we evaluated the role of sarcopenia on the outcome of patients undergoing TACE for primary and secondary liver cancer. Methods: The patients’ psoas muscle size was measured on axial computed tomography (CT) scans and normalized for the patients’ height squared. This value was referred to as the psoas muscle index (PMI). The PMI was correlated with clinical and laboratory markers. Results: While pre-interventional sarcopenia had no impact on the direct tumor response to TACE, sarcopenic patients with a pre-interventional PMI below our ideal cut-off value of 13.39 mm/m2 had a significantly impaired long-term outcome with a median overall survival of 491 days compared to 1291 days for patients with a high PMI. This finding was confirmed by uni- and multivariate Cox-regression analyses. Moreover, a progressive rapid decline in muscle mass after TACE was a predictor for an unfavorable prognosis. Conclusion: Our data suggest that sarcopenia represents a previously unrecognized prognostic factor for patients undergoing TACE therapy which might yield important information on the patients’ post-interventional outcome and should therefore be implemented into clinical stratification algorithms.Keywords
Funding Information
- H2020 European Research Council (Consolidator Grant ‘PhaseControl’ (771083))
- Deutsche Krebshilfe (Mildred-Scheel-Endowed Professorship)
- Deutsche Forschungsgemeinschaft (SFB-CRC1382/01, SFB-TRR57/P06, LU 1360/3-1)
- Ernst-Jung-Foundation Hamburg (N/A)
- IZKF (interdisciplinary center of clinical research) at RWTH Aachen (N/A)
This publication has 33 references indexed in Scilit:
- Retreatment with TACE: The ABCR SCORE, an aid to the decision-making processJournal of Hepatology, 2015
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE StudyLiver International, 2015
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 UpdateOncology, 2014
- A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancerAnnals of Oncology, 2013
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaCancer, 2011
- Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on SarcopeniaJournal of the American Medical Directors Association, 2011
- Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patientsCritical Care, 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009